GlassScriptPhysician profile
Syed S Razmi
NPI 1265420533
$11,192.78
in general payments reported to CMS, 2019-2025
45 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $633 · 2021: $1,263 · 2022: $1,528 · 2023: $1,998 · 2024: $1,973 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,004 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,003.77 |
| Education | $178.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,177.43 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,402.89 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $1,044.13 | 2019-2025 | |
| Averitas Pharma INC. | $810.27 | 2023-2025 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $669.44 | 2019-2025 | Dupixent |
| Baxter Healthcare | $644.59 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $535.41 | 2021-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $408.78 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $296.97 | 2019-2025 | Opsumit |
| Insmed, INC. | $276.37 | 2020-2025 | Arikayce |
| Mylan Specialty L.P. | $249.22 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $246.11 | 2024-2025 | Zerbaxa, Winrevair, Dificid |
| United Therapeutics Corporation | $241.58 | 2021-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $178.98 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $173.26 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Razmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.